ReviewCurrent hematologic malignancy reports2015
Elderly acute myeloid leukemia: assessing risk.
Review in Current hematologic malignancy reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Trial
- Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients with Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study.International journal of general medicine · 2021Trial
- Portable Medical Orders and Inpatient Cost at End of Life in Acute Myeloid Leukemia and Myelodysplastic Syndromes.JCO oncology practice · 2025Article
- Allo-HCT with post-transplant cyclophosphamide in older adults: similar safety and a viable option compared to younger adults.Frontiers in immunology · 2025Article
- The prognostic impact of reduced variant burden in elderly patients with acute myeloid leukemia treated with decitabine.The Korean journal of internal medicine · 2023Article
- (-)-Epigallocatechin-3-gallate induces apoptosis and differentiation in leukaemia by targeting reactive oxygen species and PIN1.Scientific reports · 2021Article
- Delirium as a Presenting Feature of Myelodysplastic Syndrome in Old Age: A Case Report.Indian journal of psychological medicine · 2021Article
- Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy.Leukemia · 2019Article
- Review
- Acute myeloid leukemia in the elderly: therapeutic options and choice.Leukemia & lymphoma · 2018Review
- Acute Myeloid Leukemia and the Bone Marrow Niche-Take a Closer Look.Frontiers in oncology · 2018Review
- Efficacy and safety of lenalidomide for the treatment of acute myeloid leukemia: a systematic review and meta-analysis.Cancer management and research · 2018Article
- Comorbidity, Physical Function, and Quality of Life in Older Adults with Acute Myeloid Leukemia.Current geriatrics reports · 2017Article
- Role of physical function in predicting short-term treatment outcome in Egyptian acute myeloid leukemia patients: a single center experience.Hematology, transfusion and cell therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Treatment of older adults with acute myeloid leukemia (AML) is challenging in part due to the difficulty of accurately predicting risks and benefits of available therapies. While older patients represent the majority of those with newly diagnosed disease, there remains no consensus regarding optimal therapy. Older age is associated with increased risk of treatment-related toxicity and worse survival compared to younger adults. Age-related outcome disparity in the setting of AML therapy is clearly attributed in part to differences in tumor biology conferring resistance to therapy. However, physiologic changes of aging that decrease treatment tolerance also influence outcomes and vary among patients of the same chronologic age. Measurable patient characteristics such as comorbidity and physical function can reflect the heterogeneity of physiologic aging among older patients and help predict resilience during and after the stress of diagnosis and treatment. To improve outcomes for older adults with AML, it will be critical to investigate the predictive utility of patient characteristics in parallel with tumor biology to improve decision-making, inform trial design, and identify actionable targets for supportive care interventions. This review will focus on available data addressing risk assessment for older adults treated for AML with a focus on patient characteristics that may reflect vulnerability to poor treatment tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.